{"id":140576,"title":"Archived 47: Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022: Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T14:13:41.830000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/summary-national-advisory-committee-immunization-november-3-2022-recommendations-use-moderna-spikevax-bivalent-mrna-50-mcg-covid-19-booster-vaccine-adults.html?wbdisable=true","snippet":"Archived 47: Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022: Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults - Canada.ca Skip to main content Skip to \"About government\" We…","rawSnapshotUrl":"/api/snapshots/raw/140576","browseUrl":"https://replay.healtharchive.ca/job-1/20250418141341/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/summary-national-advisory-committee-immunization-november-3-2022-recommendations-use-moderna-spikevax-bivalent-mrna-50-mcg-covid-19-booster-vaccine-adults.html?wbdisable=true#ha_snapshot=140576","mimeType":"text/html","statusCode":200}